Link Between Splenda And Leukemia Found

Splenda - the artificial sweetener derived from sugar - has been found to cause leukemia and cancerous tumors in mice. The product is a key ingredient in over 4,500 beverages and foods.

Results published in the International Journal of Occupational and Environmental Health claim that mice who were fed large doses of the non-nutritive sweetener developed the diseases.

For the duration of their lives, the mice were given large daily amounts of Splenda - the equivalent of a human consuming 10 Diet Cokes per day. Scientists warn, however, that even smaller doses could be dangerous to your health.

“When something causes cancer at high doses, it generally causes cancer at lower doses, the risk is just smaller,” said Lisa Lefferts, senior scientist at the Center for Science in the Public Interest (CPSI).

The sweetener to avoid

Due to results of the study, CPSI has added Splenda to its list of artificial sweeteners to avoid. The product routinely appears in grocery store items like baked goods, sugar-free gum and diet sodas.

Although CPSI suggests avoiding Splenda found in diet sodas, it also warns against drinking regular sodas. These beverages contain high fructose corn syrup and sugar - increasing the risk for type 2 diabetes, weight gain and heart disease.

CPSI scientists advise leaving the soda on the shelf and reaching for a glass of water when you’re thirsty. If you’re still craving a sweetener for your morning coffee or tea, the study recommends products like stevia and raw honey.

Source: KFOR

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap